Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016
Published Aug 10, 2016
198 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
- The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects
- The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding t

  
Source:
Document ID
GMDHC8353IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Attention Deficit Hyperactivity Disorder (ADHD) Overview131
Therapeutics Development142
  Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) Overview141
  Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) Comparative Analysis151
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics under Development by Companies164
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics under Investigation by Universities/Institutes201
Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Products Glance214
  Late Stage Products211
  Clinical Stage Products221
  Early Stage Products231
  Unknown Stage Products241
Attention Deficit Hyperactivity Disorder (ADHD) Products under Development by Companies254
Attention Deficit Hyperactivity Disorder (ADHD) Products under Investigation by Universities/Institutes291
Attention Deficit Hyperactivity Disorder (ADHD) Companies Involved in Therapeutics Development3036
  Alcobra Ltd301
  Amarantus Bioscience Holdings, Inc.311
  APeT Holding BV321
  Arbor Pharmaceuticals, LLC331
  BCWorld Pharm Co. Ltd.341
  BioLite, Inc.351
  Collegium Pharmaceutical, Inc.361
  Curemark, LLC371
  DURECT Corporation381
  Egalet Corporation391
  Eli Lilly and Company401
  Ensysce Biosciences Inc.411
  H. Lundbeck A/S421
  Heptares Therapeutics Limited431
  Highland Therapeutics, Inc.441
  Integrative Research Laboratories Sweden AB451
  Intra-Cellular Therapies, Inc.461
  INVENT Pharmaceuticals, Inc.471
  KemPharm, Inc.481
  Luc Therapeutics, Inc.491
  Medgenics, Inc.501
  Merck &Co., Inc.511
  Neos Therapeutics, Inc.521
  NeuroDerm Ltd.531
  Neurovance, Inc.541
  NLS Pharma Group551
  Noven Pharmaceuticals, Inc.561
  P2D Bioscience571
  Polleo Pharma Limited581
  Reviva Pharmaceuticals Inc.591
  Shire Plc601
  Sunovion Pharmaceuticals Inc.611
  Supernus Pharmaceuticals, Inc.621
  Taisho Pharmaceutical Co., Ltd.631
  Taisho Pharmaceutical Holdings Co., Ltd.641
  TRImaran Pharma, Inc.651
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Assessment6612
  Assessment by Monotherapy Products661
  Assessment by Combination Products671
  Assessment by Target683
  Assessment by Mechanism of Action713
  Assessment by Route of Administration742
  Assessment by Molecule Type762
Drug Profiles78101
  (nicotine + opipramol hydrochloride) Drug Profile781
  AR-08 Drug Profile791
  BCWPE-003 Drug Profile801
  BLI-1008 Drug Profile811
  BNC-375 Drug Profile821
  CB-8411 Drug Profile831
  centanafadine IR Drug Profile841
  centanafadine SR Drug Profile853
  CM-4612 Drug Profile881
  CTX-1301 Drug Profile891
  CTX-1302 Drug Profile901
  dasotraline hydrochloride Drug Profile912
  dextroamphetamine Drug Profile931
  dextroamphetamine MR Drug Profile942
  edivoxetine hydrochloride Drug Profile962
  Egalet-003 Drug Profile981
  eltoprazine Drug Profile995
  etiguanfacine Drug Profile1041
  fasoracetam Drug Profile1052
  guanfacine hydrochloride ER Drug Profile1072
  histamine dihydrochloride Drug Profile1091
  HTL-1071 Drug Profile1102
  INV-107 Drug Profile1121
  INV-170 Drug Profile1131
  IRL-752 Drug Profile1141
  ITI-214 Drug Profile1152
  KP-415 CR Drug Profile1172
  lisdexamfetamine dimesylate Drug Profile1197
  mazindol Drug Profile1261
  Metadoxine ER Drug Profile1277
  methylphenidate hydrochloride ER Drug Profile1341
  methylphenidate hydrochloride MR Drug Profile1354
  methylphenidate hydrochloride SR Drug Profile1392
  methylphenidate hydrochloride XR Drug Profile1412
  MGS-0028 Drug Profile1431
  molindone hydrochloride ER Drug Profile1442
  niacinamide CR Drug Profile1461
  NLS-3 Drug Profile1471
  NLS-4 Drug Profile1481
  NT-0201 Drug Profile1491
  P-001 Drug Profile1501
  PBF-509 Drug Profile1511
  PD-2005 Drug Profile1521
  PD-3044 Drug Profile1531
  PFR-08001 Drug Profile1541
  PFR-8026 Drug Profile1551
  RP-5063 Drug Profile1562
  SHP-465 Drug Profile1582
  Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder Drug Profile1601
  Small Molecules for Attention Deficit Hyperactivity Disorder Drug Profile1611
  Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder Drug Profile1621
  Small Molecules to Inhibit Dopamine Transporter for Attention Deficit Hyperactivity Disorder Drug Profile1631
  Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders Drug Profile1641
  Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders Drug Profile1651
  Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD Drug Profile1661
  Small Molecules to Modulate Choline Transporter for ADHD Drug Profile1671
  Synthetic Peptide to Antagonize D2 for ADHD Drug Profile1681
  TS-141 Drug Profile1691
  Vaccine for CNS Disorders Drug Profile1701
  viloxazine hydrochloride ER Drug Profile1711
  vortioxetine hydrobromide Drug Profile1726
  VU-0238429 Drug Profile1781
Attention Deficit Hyperactivity Disorder (ADHD) Dormant Projects1795
Attention Deficit Hyperactivity Disorder (ADHD) Discontinued Products1841
Attention Deficit Hyperactivity Disorder (ADHD) Product Development Milestones18512
  Featured News &Press Releases1851
    Jul 27, 2016: Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials1851
    Jul 14, 2016: KemPharm Completes Key Regulatory Meeting with FDA for KP4151861
    Jun 29, 2016: Shire Announces Positive Topline Results of SHP465 Efficacy and Safety Study in Adults with ADHD1861
    Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD1871
    Jun 16, 2016: FDA accepts IND for Phase II Study of Mazindol in Adults with ADHD1881
    Jun 06, 2016: Highland Therapeutics Announces Positive Data from Second Pivotal ADHD Trial For HLD-2001881
    May 12, 2016: NLS Pharma Announces Submission of Investigational New Drug Application to FDA for Its Controlled-Release Mazindol for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder1891
    Apr 14, 2016: Shire Submits NDA to FDA for New Formulation of Vyvanse (lisdexamfetamine dimesylate) CII as Chewable Tablets1901
    Apr 05, 2016: Highland Therapeutics Announces Positive Pivotal ADHD Trial Results for Its Investigational Drug Candidate Benjorna1902
    Apr 04, 2016: Shire Announces Positive Results of SHP465 Safety and Efficacy Study in Children and Adolescents with ADHD1921
    Mar 30, 2016: Highland Therapeutics Announces Trade Name Benjorna for Its Next-Generation ADHD Medicine1931
    Mar 04, 2016: Amarantus Appoints Brian E. Harvey, MD PhD to Strategic Advisory Board1931
    Feb 10, 2016: Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD treatment for children1941
    Jan 27, 2016: Submission of Manufacturing and Marketing Authorization Application for ADHD Medicine S - 8775031951
    Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline1961
Appendix1972
  Methodology1971
  Coverage1971
  Secondary Research1971
  Primary Research1971
  Expert Panel Validation1971
  Contact Us1971
  Disclaimer1981

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Attention-Deficit-Hyperactivity-Disorder-ADHD-Pipeline-Review-H2-2016-2088-16361>
  
APA:
Global Markets Direct - Market Research. (2016). Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Attention-Deficit-Hyperactivity-Disorder-ADHD-Pipeline-Review-H2-2016-2088-16361>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.